Fewer Than 1 in 4 Patients With HCV-Related HCC Get DAAs : v

Early uncertainty about the safety of noninterferon antivirals in patients with liver cancer may have contributed to the slow acceptance of direct-acting antiviral agents in this population.

Related Keywords

Australia , University Of California San Francisco , California , United States , Boston , Massachusetts , Palo Alto , Stanford University , Steven Bollipo , Leslie Yeeman Kam , Comoderator Jennifer , Stanford University Medical Center , Liver Meeting , American Association , Liver Diseases , Clinformatics Data Mart , John Hunter Hospital , New South Wales , Medscape Medical , California San Francisco , Hepatitis C , Cv Hepatitisc Virus , Hepatocellular Carcinoma , Liver Cancer , Dcc , Hepatocellular Cancer , Ancer Liver , Ancer Hepatocellular , Hepatitis , Viral Hepatitis , Liver Disease , Liver , Cancer , Alignant Neoplasia , Arcinoma , Biliary Disease , Allbladder Disease , Decompensated Liver Disease , Antiviral , Amciclovir , Alacyclovir , Medical Literature , Books , Textbooks , Ournals , Clinical Research , ,